Skip to main content
. 2024 Jul 12;103(28):e38911. doi: 10.1097/MD.0000000000038911

Figure 6.

Figure 6.

Images in the pink frame display all HER2 subtypes of breast cancer metastasis before T-DXd treatment, whereas images in the green frame display all HER2 subtype metastases regressing after T-DXd treatment. HER2 = human epidermal growth factor receptor 2, T-DXd = Trastuzumab Deruxtecan.